Key result
Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 analogues reduce cardiovascular events.
Why the study?
Do sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 analogues reduce cardiovascular events?
Do sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 analogues reduce cardiovascular events?
SGLT2 inhibitors and GLP-1 analogues represent a paradigm shift in clinical practice by reducing cardiovascular events.
Supports CV event reduction with SGLT2 inhibitors and GLP-1 analogues; leaves open optimal sequencing and head-to-head comparisons.
This review article summarizes the recent cardiovascular outcome data for sodium–glucose cotransporter-2 inhibitors and glucagon-like peptide-1 analogues, which have been found to reduce cardiovascular events. We also detail the implications these new medications will have on clinical practice through a review of recent diabetes guidelines and cost-effectiveness data.
No takes yet. Share an insight, caveat, or question.
Kelly et al. (2018) studied this question. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 analogues reduce cardiovascular events.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: